BROS vs TXRH

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline stability, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong revenue and earnings growth, elevated valuation multiples—P/E of 124.43 and Price/Book of 11.80—suggest the stock is pricing in aggressive future expectations. Profitability margins and ROE are above sector averages, but insider selling worth over $600M in the last six months raises concern about confidence at the top. Analysts maintain a strong_buy consensus, yet technical trend and recent price performance show weakness, indicating potential near-term headwinds.

TXRH exhibits a concerning divergence between its current market price ($161.05) and its deterministic value, with a Piotroski F-Score of 4/9 indicating only stable to weak financial health. The stock trades at a massive premium to both its Graham Number ($55.14) and Intrinsic Value ($42.70), while fundamental growth has stalled with earnings plummeting -25.9% YoY. This valuation gap is exacerbated by a streak of four consecutive earnings misses and bearish insider activity, suggesting the current price is unsupported by underlying financial performance.